Condition

Chronic lymphoid leukemia

Clinical trials and treatment information for Chronic lymphoid leukemia

721K
People Affected
80
Active Trials
108K
New Cases/Year
46K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Venetoclax + Obinutuzumab
92% Effectiveness• 95% Confidence• 38% Safety• 45 trials• 6K participants
HIGH EvidenceGood ValueDose: Venetoclax ramp-up to 400mg daily, Obinutuzumab 1000mg IV on specific days
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
38
DangerousModerateSafe

Time to Effect

3-6 months

Duration

12-24 months

Response Rate

90%

Remission Rate

60%

Common Side Effects:

Neutropenia: 50%
Infections: 37%
Diarrhea: 30%
Nausea: 25%
Tumor Lysis Syndrome: 5%

Annual Cost of Care

Drug Cost

$180,000

Monitoring

$7,000

Side Effects

$8,000

Total Annual

$195,000

Cost-Effectiveness

GOOD

QALYs Gained

1

ICER

$38,895/QALY

Cost per Remission

$325,000

Cost per Responder

$216,667

Treatment Outcomes
Primary Outcomes
Absolute Lymphocyte Count (ALC)100 x 10^9/L
-98% (-98 x 10^9/L)
Lymph Node Size (Sum of Product of Diameters)20 cm²
-90% (-18 cm²)
Bone Marrow Infiltration by CLL cells80% infiltration
-93.75% (-75% infiltration)
Secondary Benefits
Hemoglobin Level10.0 g/dL
+30% (+3.0 g/dL)
Platelet Count80 x 10^9/L
+125% (+100 x 10^9/L)
Fatigue (FACIT-Fatigue Score)FACIT-Fatigue Score: 25/52
+60% (+15 points)
Common Side Effects
Neutropenia
+50%
Infections
+37%
Diarrhea
+30%

Clinical Trial Phases:

Phase 3Phase 4
2
Zanubrutinib
90% Effectiveness• 93% Confidence• 48% Safety• 42 trials• 4.5K participants
HIGH EvidenceGood ValueDose: 160mg twice daily or 320mg once daily orally
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe

Time to Effect

1-3 months

Duration

Until progression or unacceptable toxicity

Response Rate

90%

Remission Rate

20%

Common Side Effects:

Neutropenia: 28%
Upper Respiratory Tract Infection: 20%
Bruising: 17%
Diarrhea: 16%
Muscle pain: 15%

Annual Cost of Care

Drug Cost

$160,000

Monitoring

$5,000

Side Effects

$4,000

Total Annual

$169,000

Cost-Effectiveness

GOOD

QALYs Gained

1.4

ICER

$60,490/QALY

Cost per Remission

$845,000

Cost per Responder

$187,778

Treatment Outcomes
Primary Outcomes
Absolute Lymphocyte Count (ALC)200 x 10^9/L
-95% (-190 x 10^9/L)
Sum of Product Diameters (SPD) of Target Lymph Nodes25 cm
-75% (-18.75 cm)
Spleen Size (Longest Dimension)18 cm
-50% (-9 cm)
Bone Marrow Involvement by CLL80% infiltration
-75% (-60% infiltration)
Secondary Benefits
Fatigue (EORTC QLQ-CLLM1 Scale)EORTC QLQ-CLLM1 Fatigue score: 60/100
-30% (-18 points)
Global Health Status (EORTC QLQ-C30 Scale)EORTC QLQ-C30 Global Health Status: 50/100
+20% (+10 points)
Hemoglobin Level10 g/dL
+15% (+1.5 g/dL)
Common Side Effects
Neutropenia
+28%
Upper Respiratory Tract Infection
+20%
Bruising
+17%

Clinical Trial Phases:

Phase 3Phase 4
3
Acalabrutinib
88% Effectiveness• 92% Confidence• 45% Safety• 83 trials• 7K participants
HIGH EvidenceModerate ValueDose: 100mg twice daily orally
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe

Time to Effect

1-3 months

Duration

Until progression or unacceptable toxicity

Response Rate

80%

Remission Rate

15%

Common Side Effects:

Headache: 39%
Diarrhea: 38%
Bruising: 36%
Neutropenia: 29%
Infections: 25%

Annual Cost of Care

Drug Cost

$160,000

Monitoring

$5,000

Side Effects

$4,000

Total Annual

$169,000

Cost-Effectiveness

MODERATE

QALYs Gained

1.3

ICER

$110,000/QALY

Cost per Remission

$1,126,667

Cost per Responder

$211,250

Treatment Outcomes
Primary Outcomes
Lymph Node Sum of Products of Diameters (SPD)1500 mm^2
-85% (-1275 mm^2)
Absolute Lymphocyte Count (ALC)150 x 10^9/L
-70% (-105 x 10^9/L)
Hemoglobin9.5 g/dL
+15.8% (+1.5 g/dL)
Platelet Count80 x 10^9/L
+50% (+40 x 10^9/L)
Secondary Benefits
FACIT-Fatigue Scale score20/52 (higher score is better)
+25% (+5 points)
Spleen Longest Diameter20 cm
-65% (-13 cm)
CLL Symptom Burden Score15/30 (higher score is worse)
-40% (-6 points)
Common Side Effects
Headache
+39%
Diarrhea
+38%
Bruising
+36%

Clinical Trial Phases:

Phase 3Phase 4
4
Ibrutinib
86% Effectiveness• 94% Confidence• 42% Safety• 172 trials• 8K participants
HIGH EvidencePoor ValueDose: 420mg daily orally
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
42
DangerousModerateSafe

Time to Effect

1-3 months

Duration

Until progression or unacceptable toxicity

Response Rate

85%

Remission Rate

15%

Common Side Effects:

Diarrhea: 48%
Atrial Fibrillation: 16%
Hypertension: 14%
Bleeding: 12%
Arthralgia: 10%

Annual Cost of Care

Drug Cost

$160,000

Monitoring

$5,000

Side Effects

$5,000

Total Annual

$170,000

Cost-Effectiveness

POOR

QALYs Gained

1.2

ICER

$168,782/QALY

Cost per Remission

$1,133,333

Cost per Responder

$200,000

Treatment Outcomes
Primary Outcomes
Absolute Lymphocyte Count100 x 10^9/L
-70% (-70 x 10^9/L)
Lymph Node Sum of Product of Diameters20 cm^2
-75% (-15 cm^2)
Spleen Size below Costal Margin8 cm
-60% (-5 cm)
Hemoglobin Level10.0 g/dL
+15% (+1.5 g/dL)
Secondary Benefits
Fatigue (FACIT-F Score)FACIT-F score: 30/52
+17% (+5 points)
Overall Quality of Life (EQ-5D-5L VAS)EQ-5D-5L VAS score: 60/100
+17% (+10 points)
ECOG Performance StatusECOG Performance Status: 2/5
-50% (-1 point)
Common Side Effects
Diarrhea
+48%
Atrial Fibrillation
+16%
Hypertension
+14%

Clinical Trial Phases:

Phase 3Phase 4
5
Fludarabine + Cyclophosphamide + Rituximab (FCR)
80% Effectiveness• 90% Confidence• 28% Safety• 35 trials• 10K participants
HIGH EvidenceExcellent ValueDose: Fludarabine 25mg/m2 IV, Cyclophosphamide 250mg/m2 IV, Rituximab 375mg/m2 IV (all on specific days of a 28-day cycle)
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
28
DangerousModerateSafe

Time to Effect

3-6 months

Duration

6 cycles (approx. 6 months)

Response Rate

80%

Remission Rate

40%

Common Side Effects:

Neutropenia: 50%
Infections: 30%
Anemia: 25%
Thrombocytopenia: 20%
Nausea: 20%
Fatigue: 15%

Annual Cost of Care

Drug Cost

$40,000

Monitoring

$10,000

Side Effects

$15,000

Total Annual

$65,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.8

Cost per Remission

$162,500

Cost per Responder

$81,250

Treatment Outcomes
Primary Outcomes
Absolute Lymphocyte Count (ALC)100 x 10^9/L
-90% (-90 x 10^9/L)
Minimal Residual Disease (MRD) Level in Bone MarrowMRD positive (detectable at 10^-2)
-99% (Achieve undetectable MRD (<10^-4))
Sum of Products of Perpendicular Diameters (SPD) of Target Lymph Nodes5.0 cm (SPD)
-80% (-4.0 cm (SPD))
Spleen Palpation below Costal Margin5 cm below costal margin
-90% (-4.5 cm below costal margin)
Secondary Benefits
Hemoglobin Level10.0 g/dL
+20% (+2.0 g/dL)
Platelet Count90 x 10^9/L
+50% (+45 x 10^9/L)
ECOG Performance StatusECOG PS 2
-50% (-1 point on ECOG PS scale (from 2 to 1))
Common Side Effects
Neutropenia
+50%
Infections
+30%
Anemia
+25%

Clinical Trial Phases:

Phase 3Phase 4